Cardioprotection: Where to from here?

Area of Science:

• Cardiology
• Translational Medicine

Background:

• Myocardial infarct size is a key determinant of mortality and heart failure.
• Timely reperfusion of the infarct-related artery is the primary strategy to reduce infarct size.
• Numerous preclinical therapies have failed to translate into clinical success.

Purpose of the Study:

• To review recent successes and failures in therapies targeting myocardial infarct size.
• To discuss novel preclinical therapies for myocardial infarction that await clinical trials.

Main Methods:

• Literature review of preclinical and clinical studies on myocardial infarction size reduction.
• Analysis of therapeutic strategies beyond reperfusion alone.

Main Results:

• Few pharmacologic agents and therapeutic maneuvers have successfully reduced myocardial infarct size in clinical settings.
• Significant gap exists between preclinical promise and clinical efficacy for novel therapies.

Conclusions:

• Despite numerous preclinical advancements, translating therapies to reduce myocardial infarct size remains challenging.
• Further research and innovative clinical trial designs are needed to validate promising preclinical findings.